Stock AnalizResmed (RMD) earnings for the quarter ended September 2026: EPS beats estimates
Resmed reported results for the quarter ended September 2026 on October 29, 2026. Adjusted earnings per share came in at $2.91 against the analysts’ average forecast of $2.67, a beat of 8.9%.
Revenue for the quarter was $1.41 billion, up 5.9% from $1.34 billion in the same quarter a year earlier.
The market’s verdict: the stock fell 8.1% on the first trading day after the report.
The last four quarters
Resmed has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $2.91 | $2.67 | +8.9% | +6% | −8.1% |
| Jun 2026 | $2.95 | $2.89 | +2.0% | +9% | −5.4% |
| Mar 2026 | $2.86 | $2.80 | +2.1% | +11% | −3.3% |
| Dec 2025 | $2.81 | $2.72 | +3.1% | +11% | +0.2% |
What comes next
Analysts expect EPS of $2.99 for the next quarter on average and $12.14 for the fiscal year ending June 30, 2027.
The average analyst price target is $264.33, 10% above the current price of $239.53.
Valuation and score
Resmed scores 4.2 out of 5 overall on Stock Analiz (a strong company), trades at a trailing P/E of about 21.8, and its intrinsic value under moderate assumptions is about 28% below the current market value. Full Resmed analysis with 10 years of financials
Frequently asked questions
What was Resmed’s EPS for the quarter ended September 2026?
$2.91 adjusted per share, against an analyst consensus of $2.67.
How much revenue did Resmed report?
$1.41 billion, up 5.9% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.